Clinical Trial Detail

NCT ID NCT02752685
Title Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors New York University School of Medicine
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Nab-paclitaxel + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST